JPM: Bristol chief says one-third of Celgene cost cuts will hit in 2020

via Last year, Bristol-Myers Squibb stole the show at the J.P. Morgan Healthcare Conference with its $74 billion deal agreement for Celgene. But one year later, with the deal just recently closed, company CEO Giovanni Caforio says he feels “even better about our opportunity” then he did when BMS unveiled it.

article source